相关实验视频

Updated: Jun 12, 2025

Author Spotlight: Advancing Reproductive Immunology with a Protocol for the Quantitative Evaluation of Endometrial Immune Cells

Author Spotlight: Advancing Reproductive Immunology with a Protocol for the Quantitative Evaluation of Endometrial Immune Cells

Published on: October 13, 2023

激活的免疫透物扩大了针对p53-异常子宫内膜癌的向治疗机会

Spencer D Martin¹, Shelby Thornton², Christine Chow²

¹Department of Pathology and Laboratory Medicine, Faculty of Medicine, The University of British Columbia, Vancouver, Canada.

The Journal of pathology

|April 14, 2025

概括

瘤蛋白p53突变/异常 (p53abn) 子宫内膜癌的治疗反应不佳. 这项研究发现,具有高瘤透淋巴细胞 (TILs) 的p53abn瘤显示出更好的生存率,并可能从免疫疗法中受益.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
病理学病理学病理学

背景情况:

带有突变/异常瘤蛋白p53 (p53abn) 的子宫内膜癌具有攻击性,对标准治疗反应不佳.
虽然免疫疗法在某些子宫内膜癌中表现有前途,但p53abn亚型的免疫微环境,特别是不匹配修复能力 (MMRp) 的免疫微环境,尚不清楚.
了解p53abn子宫内膜癌的免疫细胞透和可向的变化对于开发有效疗法至关重要.

研究的目的:

为了描述p53abn子宫内膜癌的免疫微环境.
为了将抗瘤免疫特征与其他可向的分子变化相关联.
为了确定潜在的治疗策略,包括免疫疗法,对于这种侵略性癌症亚型.

主要方法:

在256例未经治疗的p53abn子宫内膜癌中使用多重免疫光学对免疫细胞群 (T细胞,B细胞,髓状细胞) 和瘤细胞进行系统分析.
在126个病例中进行浅层全基因组测序,以评估突变特征.
分析免疫透模式与生存结果和可向变化的关系.

主要成果:

p53abn子宫内膜癌被分为瘤透性淋巴细胞 (TIL) 丰富和TIL贫乏的子集,超过50%是富含TIL的.
富含TIL的瘤过度表达了免疫逃避分子,并且与明显更长的整体和疾病特异性存活率有关.
TILs与同类重组缺陷特征或HER2放大无关,这表明有不同的生物驱动因素.

结论:

一个相当大的p53abn子宫内膜癌的子集表现出与改善的生存相关的免疫丰富的微环境.
这些发现为p53abn子宫内膜癌的免疫治疗提供了生物学理由.
这些结果可以指导涉及免疫检查点抑制剂,PARP抑制剂和抗HER2剂的组合疗法.

关键词:

在HER2中,HER2是HER2.在 PARP 抑制剂.这是子宫内膜癌的癌症.免疫疗法免疫疗法 p53abn 在线阅读瘤微环境是一个微环境.入瘤的淋巴细胞

更多相关视频

Non-Invasive Ultrasound Assessment of Endometrial Cancer Progression in Pax8-Directed Deletion of the Tumor Suppressors Arid1a and Pten in Mice

Non-Invasive Ultrasound Assessment of Endometrial Cancer Progression in Pax8-Directed Deletion of the Tumor Suppressors Arid1a and Pten in Mice

Published on: February 17, 2023

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.